HIV Pre-exposure Prophylaxis Implementation Hong Kong Study

Completed

• Conditions: HIV Infections

• Registration Number: NCT04367688
• Lead Sponsor: Chinese University of Hong Kong

Brief Summary

While pre-exposure prophylaxis (PrEP) is widely recommended and a number of pilot studies are on-going worldwide, progress of its implementation in the real world setting has been slow, especially in Asia. This study aims to develop a service model for PrEP delivery and test its operability in the real world setting. In this implementation study, 400 individuals with high sexual risk of HIV infection who fulfil eligibility criteria would be recruited. Eligible participants would receive one year of daily tenofovir disoproxil fumarate 300mg / emtricitabine 200mg (TDF/FTC) for free. A client-initiated approach would be adopted, requiring participants to self-arrange for regular HIV/sexually transmitted infections (STI) testing. An online system would be developed to facilitate participants to plan for testing and consultation for accessing PrEP. Questionnaire at baseline and subsequent monthly follow-up would be administered to assess behaviour, monitor adverse effects and drug adherence, the latter coupled with the completion of an online diary. Testing of HIV and creatinine would be performed using point-of-care test or by phlebotomy during clinical visits. Blood samples would be collected for archiving. Around 40 participants would be invited to join an in-depth interview in the later part of the study to evaluate the service model. The main outcome measures are: PrEP service adherence, PrEP drug adherence, prevalence of drug intolerance, prevalence of unprotected sex in the study period, incidence of HIV and STI

Detailed Description

Not available

Study Timeline

• Study Start: 2020-03-01
• Study First Submitted: 2020-04-26
• Study First Submitted QC: 2020-04-26
• Study First Posted: 2020-04-29
• Primary Completion: 2023-09-30
• Study Completion: 2024-01-31
• Status Verified: 2024-02
• Last Update Submitted: 2024-02-05
• Last Update Posted: 2024-02-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 339

Inclusion Criteria

• Can communicate in written and spoken English or Chinese
• Is normally resident in Hong Kong
• Has tested HIV antibody negative in the past 3 months
• Has more than 1 episode of unprotected sex (especially anal sex) in the preceding 6 months
• Has any one of the following experiences in the past 6 months: chemsex engagement, group sex, multiple sex partners, STI diagnosis, having sex partner(s) with HIV+ve status
• Is inclined to engage in high risk sexual activities

Read More

Exclusion Criteria

• Chronic HBV infection (HBsAg +ve)
• Impaired renal function, defined as estimated glomerular filtration rate (eGFR) < 60mL/min/1.73m2
• Having any form of mental illnesses
• Inability or refusal to give consent
• Prisoners or any institutionalised persons
• Pregnant or planning to get pregnant (for female)
• Injection drug user

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
adherence to PrEP service	12 months	attending the PrEP service with prescription and HIV tests regularly in accordance with protocol
adherence to PrEP regimen	12 months	proportion adherent to daily TDF/FTC

Trial Locations

Locations (1)

Prince of Wales Hospital; 🇭🇰 Hong Kong, Hong Kong